Corticorelin Ovine Triflutate

Summary

Corticorelin Ovine Triflutate (CHEMBL1201591) is an approved protein; indicated across 1 condition including adenoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• Indications: 1 condition
• Clinical trials: 4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201591
Name	Corticorelin Ovine Triflutate
Type	Protein
Max phase	4

Also known as: Acthrel, Corticorelin ovine triflutate, CORTICORELIN OVINE TRIFLUTATE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
adenoma	4	MONDO:0004972	EFO:0000232

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
Not specified	2
EARLY_PHASE1	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01673087	PHASE1	COMPLETED	Stress Biomarkers:Attaching Biological Meaning to Field Friendly Salivary Measures
NCT01459237	EARLY_PHASE1	COMPLETED	Effects of Hormone Stimulation on Brain Scans for Cushing s Disease
NCT00756925	Not specified	COMPLETED	Gender and Neural Substrates of Stress and Craving
NCT01373372	Not specified	WITHDRAWN	Corticotropin Releasing Hormone (CRH) Responsiveness in Children With Functional Dyspepsia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).